Clinical Trial Update: JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial update indicates that JY232 injection is being studied for relapsed/refractory multiple myeloma and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JY232

Snippet

Sponsor: Shenzhen Genocury Biotech Co., Ltd. | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING